Molecular Partners
MOLN
6 hedge funds and large institutions have $15.6M invested in Molecular Partners in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
17% more capital invested
Capital invested by funds: $13.3M → $15.6M (+$2.27M)
0.02% more ownership
Funds ownership: 8.87% → 8.89% (+0.02%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$20.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$582 |
| 3 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
-$535 |
MOLN Hedge Fund Activity: Q4 2025 in Review
6 of the 8,264 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q4 2025, worth a combined $15.6M — up 17% from $13.3M a quarter earlier.
Fund positioning in MOLN was balanced in Q4 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was UBS Group, cutting an estimated $20.4K.
- 6 institutional investors held Molecular Partners (MOLN) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $15.6M of Molecular Partners stock for Q4 2025, up 17% quarter-over-quarter.
- 1 fund opened new Molecular Partners positions in Q4 2025 and 1 closed out, a net change of 0 holders.
- The largest Molecular Partners seller in Q4 2025 was UBS Group, an estimated $20.4K sold.
Based on aggregated 13F filings for Q4 2025.